Last €19.63 EUR
Change Today +0.91 / 4.87%
Volume 65.0
44A On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 9:56 AM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

anacor pharmaceuticals inc (44A) Snapshot

Open
€19.10
Previous Close
€18.72
Day High
€19.63
Day Low
€18.83
52 Week High
09/12/14 - €19.74
52 Week Low
09/26/13 - €7.35
Market Cap
824.5M
Average Volume 10 Days
17.4
EPS TTM
--
Shares Outstanding
42.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ANACOR PHARMACEUTICALS INC (44A)

anacor pharmaceuticals inc (44A) Related Businessweek News

No Related Businessweek News Found

anacor pharmaceuticals inc (44A) Details

Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company’s lead product candidates include tavaborole, an antifungal product candidate that is in Phase III clinical development for the treatment of onychomycosis; and AN2728, an anti-inflammatory product candidate, which completed Phase II clinical trials for the treatment of atopic dermatitis and psoriasis, and chronic inflammatory skin diseases. It also develops AN5568, a Phase I human clinical trial product targeting human African trypanosomiasis; and other compounds to treat animal health indications. The company’s clinical pipeline also includes AN2718, a topical antifungal product candidate, which is in Phase I clinical trials for the treatment of onychomycosis and fungal infections of the skin; AN2898, a topical anti-inflammatory product candidate that completed Phase IIa clinical trials for the treatment of atopic dermatitis and psoriasis; and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. It has research, development, and collaboration agreements with GlaxoSmithKline LLC, Eli Lilly and Company, Schering Corporation, Medicis Pharmaceutical Corporation, Bill and Melinda Gates Foundation, and Medicines for Malaria Ventures. The company was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in October 2002. Anacor Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Palo Alto, California.

79 Employees
Last Reported Date: 03/17/14
Founded in 2000

anacor pharmaceuticals inc (44A) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $335.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $335.0K
Senior Vice President of Program Management
Total Annual Compensation: $330.0K
Senior Vice President of Drug Development
Total Annual Compensation: $272.5K
Senior Vice President of Research
Total Annual Compensation: $335.0K
Compensation as of Fiscal Year 2013.

anacor pharmaceuticals inc (44A) Key Developments

Anacor Pharmaceuticals Appoints Wendell Wierenga as Class III Director

Anacor Pharmaceuticals, Inc. announced that its Board of Directors has appointed Wendell Wierenga, Ph.D. to serve as a Class III director until the company's 2016 annual meeting of shareholders. Anacor also announced that Paul Klingenstein has resigned from the Board. Dr. Wierenga is a seasoned pharmaceutical executive with broad experience in all aspects of research, drug discovery and drug development. From June 2011 until February 2014, Dr. Wierenga served as Executive Vice President, Research and Development of Santarus, Inc.

Anacor Pharmaceuticals, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 03:30 PM

Anacor Pharmaceuticals, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 03:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Paul L. Berns, Chairman, Chief Executive Officer, President, Chairman of Compensation Committee, Chairman of Transaction Committee and Member of Audit Committee.

Anacor Pharmaceuticals, Inc. Provides Financial Guidance for the Remainder of the Year 2014

Anacor Pharmaceuticals, Inc. provided financial guidance for the remainder of the year 2014. Contract revenue related to neglected disease partnerships is expected to continue to be approximately $3 million per quarter. Interest expense will continue to be approximately $1.1 million per quarter in 2014. The company currently expects that the company will have at least $110 million in cash at year end 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
44A:GR €19.63 EUR +0.91

44A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 44A.
View Industry Companies
 

Industry Analysis

44A

Industry Average

Valuation 44A Industry Range
Price/Earnings 15.4x
Price/Sales 54.1x
Price/Book 12.3x
Price/Cash Flow 15.2x
TEV/Sales 46.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANACOR PHARMACEUTICALS INC, please visit www.anacor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.